多而不精:预防性报告偏倚对安全信号检测影响的探索性研究
该研究在荷兰评估预防性报告对药物不良反应数据库安全信号检测的影响,通过文本挖掘筛查三个案例产品的报告以识别缺乏因果关系的报告。结果显示预防性报告既掩盖真实安全信号又产生虚假信号,改变不良事件安全性特征,提示需加强监管机构与上市许可持有人之间的药物警戒指南协调。
要点
- 预防性报告会掩盖真实安全信号并产生虚假信号
- 预防性报告偏倚改变不良事件安全性特征
- 需协调监管机构与上市许可持有人的药物警戒指南
核心结论
- 预防性报告妨碍药物警戒系统的优化使用,既掩盖安全信号又产生虚假信号。
研究设计与样本
- 在荷兰开展的探索性研究,对三个案例产品的药物不良反应报告进行文本挖掘筛查以识别缺乏因果关系的报告。
主要发现
- 预防性报告一方面掩盖安全信号,另一方面产生虚假信号。
- 预防性报告偏倚及其对统计信号检测的抑制效应导致不良事件安全性特征发生改变。
临床怎么用
- 临床药师应关注药物警戒数据库中预防性报告对信号检测的干扰,避免因非价值报告影响安全信号判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Concerns have been expressed that large numbers of nonvalue-added reports have been accumulating in adverse drug reaction (ADR) databases, for example, via patient support programs. We performed an assessment of the impact of such reports, which we refer to as "precautionary reports," on safety signal detection in the Netherlands. The case narratives of ADR reports of three case products were screened with text-mining algorithms to identify those reports that lack a causal relationship with the suspected medicinal product. We demonstrate that precautionary reports impede the optimal use of the pharmacovigilance system by, on the one hand, masking safety signals and, on the other hand, creating spurious signals. The precautionary reporting bias and its suppressing effect on statistical signal detection results in an altered adverse event safety profile. The findings from this study highlight the need for a better alignment between regulatory authorities and marketing authorization holders regarding pharmacovigilance guidelines.
引用
- Klein K, Scholl JHG, De Bruin ML, et al. When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection. Clin Pharmacol Ther. 2017. PMID: 28913827. doi:10.1002/cpt.879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。